"Designing Growth Strategies is in our DNA"

Adult Malignant Glioma Therapeutics Market Size, Share and Industry Analysis Product By Therapy (Chemotherapy, Radiotherapy, Targeted therapy) By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma) By End User, and Regional Forecast 2019-2032

Last Updated: April 29, 2024 | Format: PDF | Report ID: FBI100572



Play Audio Listen to Audio Version

The global adult malignant glioma therapeutics market size stood at USD 1,459.1 million in 2018 and is projected to reach USD 5,362.5 million by the end of 2032, exhibiting a CAGR of 9.8% during the forecast period (2018-2032).

Gliomas are the type of tumor starting at glial cells of the brain and spine are the most common types of brain tumors. According to Atlas of Genetics and Cytogenetics in Oncology and Hematology, glioma comprises of about 30% of the brain tumors and 70% of all the malignant tumors. Glioblastoma multiforme (GBM) is the most aggressive and difficult to treat form of the disease with median survival rate of 12 months.

Growing prevalence of the disease, huge unmet need, poor survival rate, and lack of effective therapies for the complete cure of the disease leverages great opportunity for the players to invest in the research and development of glioma therapies. Currently, available therapies prescribed for adult malignant glioma therapy include surgery, chemotherapy, radiation therapy, and targeted therapies among others.

The adult malignant glioma therapeutics market share is anticipated to expand at near two digit CAGR during the forecast period attributable to supportive government and regulatory policies for the development of novel therapies, advancements in the imaging technologies resulting in early detection of the disease, and favorable reimbursement policies for the glioma products across many regions of the world.

Request a Free sample to learn more about this report.

"Targeted therapy is expected to emerge as the most attractive treatment type"

Glioblastoma Multiforme, the most aggressive and reoccurring form of the disease is treated with first-line therapy and second-line therapy. The first line of therapies prescribed conventionally are temozolomide and radiotherapy. However, once the reoccurrence of the disease occurs, the treatment options are limited. Fortunately, advances in drug development have resulted in the successful applications of targeted therapies to improve the survival rate. Commonly used targeted therapies in the treatment of glioma are EGFR-targeted therapies, therapies targeting tyrosine kinases receptors, etc. The targeted therapy segment is projected to expand at the highest CAGR during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

In terms of disease type, the glioblastoma multiforme (GBM) held the largest adult malignant glioma therapeutic market share in the year 2018. The segment is likely to continue dominance during the forecast period. In terms of end-user, the hospital's segment accounted for a major market share. However, cancer and radiation therapy centers segment is projected to expand at the highest CAGR during the forecast period owing to the availability of medical care specific for cancer treatment

Regional Analysis

"High Prevalence of Malignant Glioma and Huge Spending on Healthcare in North America are Contributing to the Dominance of the Region in The Global Adult Malignant Glioma Therapeutics Market"

Glioblastoma multiforme is a malignant astrocytoma and the most common primary brain tumor among adults. According to the American Society of Clinical Oncology (ASCO), about 17,000 new cases of high-grade gliomas, or HGG, are expected to be diagnosed in the U.S. in 2019. Rise in the incidence of the disease, strong economy, huge spending on the healthcare, high diagnosis rate owing to awareness about the healthcare among the population are predominant factors contributing the dominance of the region in the market trend.

North America Adult Malignant Glioma Market, 2018

To get more information on the regional analysis of this market, Request a Free sample

Key Market Players 

"Merck & Co., Inc. and F. Hoffmann-La Roche Ltd to Account for Major Market Share in Terms of Revenue"

Temozolomide is the Merck & Co., Inc.’s leading product available in the U.S. as temodar and internationally as temodal. The company has a well-established footprint across the major markets. Moreover, its strategies to expand in the emerging economies are making the company leader in the glioma therapeutics. Roche dominates the adult malignant glioma therapeutic market with its leading product Avastin, approved for the treatment of malignant glioma due to strong clinical pieces of evidence supporting treatment merits.


  • Merck & Co., Inc.

  • Hoffmann-La Roche Ltd

  • Arbor Pharmaceuticals

  • Pfizer Inc.

  • AbbVie Inc.

  • Amgen Inc.

  • Bristol-Myers Squibb Company

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

  • Novocure

  • Other Key Players

Key Industry Developments

  • July 2021 - Basilea Pharmaceutica Ltd., announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to the company’s tumor checkpoint controller, lisavanbulin, for the treatment of patients suffering with malignant glioma.

  • May 2021 - Novocure GmbH entered into a clinical trial collaboration with GT Medical Technologies, Inc., in order to develop Tumor Treating Fields (TTF) in combination with GT Medical’s GammaTile Surgically Targeted Radiation Therapy (STaRT) for treatment of recurrent glioblastoma.

  • January 2020 - Pfizer Inc., introduced three new biosimilars i.e. Zirabev (Avastin), Ruxience (Rituxan) and Trazimera (Herceptin) at a discounted price in the U.S. market. Among these, Zirabev was approved for five types of cancer including recurrent glioblastoma.

Report Coverage

An Infographic Representation of Adult Malignant Glioma Therapeutics Market

To get information on various segments, share your queries with us

Glioma is a type of tumor that arises in the glial cells of the brain or spine. These comprise of around 30-40% of the primary central nervous system tumors and about 70-80% of all the malignant brain tumors. Unmet medical needs, increase in the global prevalence of the disease, and growing affordability for advanced therapies such as targeted therapies are likely to augment the demand for products designed for the treatment of adult malignant glioma.

The glioblastoma multiforme is the most common form of the glioma occurring in the adult population. It is the deadliest form of the disease requiring high end of medical care. Despite the continuous increase in the global patient population of glioma, the incidence is still less and the products approved for the treatment comes under the orphan category. The high cost of product development and less patient population are the major factors hindering the entry of new players in the market.

The adult malignant glioma therapeutics market report provides qualitative and quantitative insights on adult malignant glioma therapeutics and detailed analysis of market size and growth rate, growth opportunities for all possible segments in the market. The market is segmented by therapy, disease type, the end-user, and region. In terms of therapy, the market segmented into chemotherapy, radiation therapy, targeted therapy, and others.

In terms of disease type, the market is studied for segments such as glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, and others. Various end-users covered under the report are hospitals, specialty clinics, cancer and radiation therapy centers, others. Geographically, the market is segmented into four major regions, which are North America, Europe, Asia Pacific, and the rest of the World. The regions are further categorized into countries.

Along with this, the report provides elaborative analysis of the adult malignant glioma therapeutics market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of glioma by key countries, an overview of technological advancements in the glioma therapy, recent industry developments such as mergers & acquisitions, and pipeline analysis.




By Therapy

  • Chemotherapy

  • Radiotherapy

  • Targeted therapy

  • Others

By Disease

  • Glioblastoma Multiforme

  • Anaplastic Astrocytoma

  • Anaplastic Oligodendroglioma

  • Others

By End User

  • Hospitals

  • Specialty Clinics

  • Cancer and Radiation Therapy Centers

  • Others

By Geography

  • North America (USA and Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

  • Rest of the World

Frequently Asked Questions

As per our (Fortune Business Insights) study, the global adult malignant glioma therapeutics market is predicted to reach US$ 2,964.5 Mn by 2026 with a CAGR of 9.3% (2019 -2026).

Unmet medical needs, an increase in the global prevalence of the glioma disease, and growing affordability for advanced therapies such as targeted therapies are some of the key factors likely to drive the market during the forecast period.

The radiation therapy segment is the leading segment in the market by drug class.

North America is anticipated to hold the highest market share in the market, and a high diagnosis rate owing to the growing awareness among the population about available therapy options are attributable to the high prevalence of malignant glioma and huge spending on healthcare.

Merck & Co., Inc. and F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals, Pfizer Inc., and AbbVie Inc are some of the leading players in the adult malignant glioma therapeutics industry.

In terms of disease type, the glioblastoma multiforme (GBM) segment held the largest market share in the market in the year 2018.

Growing advancements in drug development have resulted in the successful applications of targeted therapies, which is likely to improve the survival rate in patients with glioblastoma multiforme, which is majorly attributable to targeted therapy segment to expand at the highest CAGR during the forecast period.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • 2019-2032
    (In Process)
  • 2023
    (In Process)

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.